Search by Drug Name or NDC

NDC 72786-0111-03 OXBRYTA 300 mg/1 Details

OXBRYTA 300 mg/1

OXBRYTA is a ORAL TABLET, FOR SUSPENSION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Global Blood Therapeutics, Inc, A subsidiary of Pfizer Inc.. The primary component is VOXELOTOR.

MedlinePlus Drug Summary

Voxelotor is used to treat sickle cell disease (an inherited blood disease) in adults and children 4 years of age and older. Voxelotor is in a class of medications called hemoglobin S (HbS) polymerization inhibitors. It works by helping hemoglobin (a protein in red blood cells) to hold onto more oxygen and to stop red blood cells from becoming misshapen.

Related Packages: 72786-0111-03
Last Updated: 12/01/2022
MedLinePlus Full Drug Details: Voxelotor

Product Information

NDC	72786-0111
Product ID	72786-111_e27a3e07-438e-49d3-aae3-095e9379c7b4
Associated GPIs	82805080007320
GCN Sequence Number	082925
GCN Sequence Number Description	voxelotor TAB SUSP 300 MG ORAL
HIC3	N1H
HIC3 Description	SICKLE CELL ANEMIA AGENTS
GCN	51717
HICL Sequence Number	046225
HICL Sequence Number Description	VOXELOTOR
Brand/Generic	Brand
Proprietary Name	OXBRYTA
Proprietary Name Suffix	n/a
Non-Proprietary Name	Voxelotor
Product Type	HUMAN PRESCRIPTION DRUG
Dosage Form	TABLET, FOR SUSPENSION
Route	ORAL
Active Ingredient Strength	300
Active Ingredient Units	mg/1
Substance Name	VOXELOTOR
Labeler Name	Global Blood Therapeutics, Inc, A subsidiary of Pfizer Inc.
Pharmaceutical Class	Cytochrome P450 3A4 Inhibitors [MoA], Hemoglobin S Polymerization Inhibitor [EPC], Hemoglobin S Polymerization Inhibitors [MoA]
DEA Schedule	n/a
Marketing Category	NDA
Application Number	NDA216157
Listing Certified Through	2024-12-31

Package

NDC 72786-0111-03 (72786011103)

Pricing Information	N/A
NDC Package Code	72786-111-03
Billing NDC	72786011103
Package	90 TABLET, FOR SUSPENSION in 1 BOTTLE, PLASTIC (72786-111-03)
Marketing Start Date	2021-12-17
NDC Exclude Flag	N